Astex Therapeutics Limited

POWER SEARCH PRICING

SOLUTIONS

astex therapeutics limited Company Information

Live

MatureMegaRapid

Company Number

03751674

Website

http://astx.com

Registered Address

436 cambridge science park, milton road, cambridge, CB4 0QA

Industry

Research and experimental development on biotechnology

Telephone

01223226200

Next Accounts Due

September 2025

Group Structure

View All

Directors

Harren Jhoti25 Years

Robert McQuade10 Years

View All

Shareholders

otsuka america inc 100%

astex therapeutics limited Estimated Valuation

£1.7b

Pomanda estimates the enterprise value of ASTEX THERAPEUTICS LIMITED at £1.7b based on an EBITDA of £145.9m and a 11.97x industry multiple (adjusted for size and gross margin).

Edit your figures and get a professional valuation report.

Astex Therapeutics Limited is a live company located in cambridge, CB4 0QA with a Companies House number of 03751674. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in April 1999, it's largest shareholder is otsuka america inc with a 100% stake. Astex Therapeutics Limited is a mature, mega sized company, Pomanda has estimated its turnover at £202.5m with rapid growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Astex Therapeutics Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 9 measures and has 2 areas for improvement. Company Health Check FAQs

Health Rating5out of 5

9 Strong

0 Regular

2 Weak

Size

annual sales of £202.5m, make it larger than the average company (£3.7m)

Growth

3 year (CAGR) sales growth of 37%, show it is growing at a faster rate (11.4%)

EXPORT

Astex Therapeutics Limited's latest turnover from December 2023 is £202.5 million and the company has net assets of £136 million. According to their latest financial statements, Astex Therapeutics Limited has 166 employees and maintains cash reserves of £75.8 million as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Turnover	202,455,603	117,178,479	92,355,171	79,022,451	76,516,397	72,199,766	55,493,232	54,148,447	38,192,237	33,347,903	5,579,698	8,238,482	13,770,634	9,030,742	9,992,398
Other Income Or Grants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cost Of Sales	57,368,187	43,334,514	45,014,500	37,800,581	37,370,665	34,061,714	27,225,490	28,198,494	19,722,849	16,850,320	2,947,636	4,266,445	6,746,287	4,211,300	0
Gross Profit	145,087,416	73,843,965	47,340,671	41,221,870	39,145,732	38,138,052	28,267,742	25,949,953	18,469,388	16,497,583	2,632,062	3,972,037	7,024,347	4,819,442	0
Admin Expenses	6,381,929	4,780,566	1,821,770	6,508,003	5,576,186	6,789,708	19,310,710	4,581,071	9,646,827	9,223,094	26,208,090	21,035,547	13,567,032	12,111,145	3,801,516
Operating Profit	138,705,487	69,063,399	45,518,901	34,713,867	33,569,546	31,348,344	8,957,032	21,368,882	8,822,561	7,274,489	-23,576,028	-17,063,510	-6,542,685	-7,291,703	-3,801,516
Interest Payable	3,064,907	1,547,518	565,463	1,419,477	1,102,178	0	87,507	0	0	0	0	0	0	121,627	574,320
Interest Receivable	925,535	5,786,929	747,700	75,291	132,827	195,965	29,130	98,102	55,506	39,370	13,209	25,056	114,636	190,984	42,771
Pre-Tax Profit	136,566,115	73,302,810	45,701,138	33,369,681	32,600,195	31,544,309	8,818,765	21,082,790	8,878,067	7,313,859	-23,562,819	-17,038,454	-6,428,049	-7,222,346	-4,333,065
Tax	-14,565,802	-7,576,453	-5,833,480	-3,507,011	-3,601,065	-3,538,171	790,041	3,993,599	-12,040	-8,350	-26,454	3,058,167	2,006,183	2,491,194	1,316,900
Profit After Tax	122,000,313	65,726,357	39,867,658	29,862,670	28,999,130	28,006,138	9,608,806	25,076,389	8,866,027	7,305,509	-23,589,273	-13,980,287	-4,421,866	-4,731,152	-3,016,165
Dividends Paid	75,000,000	50,000,000	25,000,000	25,000,000	23,748,963	12,000,000	28,000,000	0	0	0	0	0	0	0	0
Retained Profit	47,000,313	15,726,357	14,867,658	4,862,670	5,250,167	16,006,138	-18,391,194	25,076,389	8,866,027	7,305,509	-23,589,273	-13,980,287	-4,421,866	-4,731,152	-3,016,165
Employee Costs	22,614,343	19,879,076	18,051,191	16,665,160	14,971,144	14,175,376	12,808,641	11,722,634	10,678,458	9,261,274	10,608,630	8,231,359	8,056,547	6,117,747	6,061,018
Number Of Employees	166	157	156	142	140	132	117	102	95	81	70	88	85	74	72
EBITDA*	145,894,136	75,531,903	51,444,089	39,561,005	38,016,566	33,553,656	10,476,135	22,568,667	9,938,771	8,104,498	-22,893,782	-16,431,586	-6,080,668	-6,773,548	-3,104,022

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Tangible Assets	50,209,301	48,707,256	46,450,076	49,762,374	43,660,887	19,848,386	18,012,279	9,911,393	4,673,801	3,746,233	2,583,685	2,616,869	2,512,099	2,267,055	2,347,160
Intangible Assets	242,084	346,105	389,306	249,862	187,448	208,478	129,872	25,889	33,851	46,120	7,673	14,510	7,634	13,963	10,944
Investments & Other	8,648,628	7,991,185	4,921,759	6,138,344	5,545,643	4,315,773	2,198,513	962,850	0	0	0	0	0	0	0
Debtors (Due After 1 year)	0	0	2,049,024	0	1,106,562	0	0	0	0	0	0	0	0	0	0
Total Fixed Assets	50,451,385	49,053,361	46,839,382	50,012,236	43,848,335	20,056,864	18,142,151	9,937,282	4,707,652	3,792,353	2,591,358	2,631,379	2,519,733	2,281,018	2,358,104
Stock & work in progress	0	0	0	0	0	0	0	0	0	0	0	0	0	45,558	47,282
Trade Debtors	6,944,359	1,079,210	607,614	823,829	8,411,627	12,598,677	4,940,379	6,540,682	2,820,399	6,139,610	2,243,638	0	3,138,742	1,936,500	100,000
Group Debtors	5,754,964	4,773,713	4,613,252	5,373,836	0	0	0	0	0	0	0	0	0	0	0
Misc Debtors	44,715,664	24,857,940	17,777,468	12,448,895	2,100,360	3,005,267	4,645,287	6,024,772	1,963,972	2,171,434	1,187,419	1,412,619	1,119,081	1,112,267	1,131,540
Cash	75,794,372	38,101,162	32,385,438	17,706,970	23,936,010	16,609,707	8,063,278	33,247,652	21,013,248	10,184,159	4,006,206	1,491,100	8,120,864	10,080,657	13,356,342
misc current assets	5,028,453	3,082,762	3,207,419	2,484,260	0	1,882,815	2,913,056	0	0	0	3,002,031	3,028,485	1,917,394	8,974,065	16,274,005
total current assets	138,795,915	72,309,024	58,591,191	38,837,790	37,700,504	34,096,466	20,562,000	45,813,106	25,797,619	18,495,203	10,439,294	5,932,204	14,296,081	22,149,047	30,909,169
total assets	189,247,300	121,362,385	105,430,573	88,850,026	81,548,839	54,153,330	38,704,151	55,750,388	30,505,271	22,287,556	13,030,652	8,563,583	16,815,814	24,430,065	33,267,273
Bank overdraft	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bank loan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Trade Creditors	449,652	360,509	620,042	1,205,985	893,054	1,199,215	847,854	641,591	1,161,104	1,497,398	323,560	1,988,425	1,963,778	1,260,355	741,524
Group/Directors Accounts	0	0	0	0	0	0	0	0	0	0	0	0	199,357	0	0
other short term finances	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,774,317
hp & lease commitments	2,953,136	2,345,321	2,068,011	2,085,155	2,101,362	0	0	0	0	0	0	0	0	0	0
other current liabilities	17,236,799	5,585,929	6,877,770	5,069,286	4,921,028	3,377,836	4,286,157	3,147,463	2,459,222	2,771,240	43,244,720	13,093,815	5,621,076	6,009,025	4,817,790
total current liabilities	20,639,587	8,291,759	9,565,823	8,360,426	7,915,444	4,577,051	5,134,011	3,789,054	3,620,326	4,268,638	43,568,280	15,082,240	7,784,211	7,269,380	8,333,631
loans	36,334,766	34,633,900	33,531,720	36,784,362	39,836,286	0	0	0	0	0	0	0	0	0	0
hp & lease commitments	18,167,383	17,316,950	16,765,860	18,392,181	19,918,143	0	0	0	0	0	0	0	0	0	0
Accruals and Deferred Income	8,317,222	0	0	483,650	0	0	0	0	0	0	0	0	1,805,561	5,694,448	9,861,112
other liabilities	540,547	1,185,824	882,280	640,474	139,844	0	0	0	0	0	0	0	0	0	0
provisions	11,100,310	11,071,518	9,821,748	5,070,434	0	0	0	0	0	0	0	0	0	0	0
total long term liabilities	32,575,307	24,038,533	22,559,014	22,051,522	20,057,987	0	0	0	0	0	0	0	1,805,561	5,694,448	9,861,112
total liabilities	53,214,894	32,330,292	32,124,837	30,411,948	27,973,431	4,577,051	5,134,011	3,789,054	3,620,326	4,268,638	43,568,280	15,082,240	9,589,772	12,963,828	18,194,743
net assets	136,032,406	89,032,093	73,305,736	58,438,078	53,575,408	49,576,279	33,570,140	51,961,334	26,884,945	18,018,918	-30,537,628	-6,518,657	7,226,042	11,466,237	15,072,530
total shareholders funds	136,032,406	89,032,093	73,305,736	58,438,078	53,575,408	49,576,279	33,570,140	51,961,334	26,884,945	18,018,918	-30,537,628	-6,518,657	7,226,042	11,466,237	15,072,530

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009
Operating Activities
Operating Profit	138,705,487	69,063,399	45,518,901	34,713,867	33,569,546	31,348,344	8,957,032	21,368,882	8,822,561	7,274,489	-23,576,028	-17,063,510	-6,542,685	-7,291,703	-3,801,516
Depreciation	6,990,212	6,304,227	5,811,798	4,765,022	4,350,719	2,142,416	1,475,371	1,175,955	1,094,460	810,638	675,409	624,849	455,688	511,276	690,735
Amortisation	198,437	164,277	113,390	82,116	96,301	62,896	43,732	23,830	21,750	19,371	6,837	7,075	6,329	6,879	6,759
Tax	-14,565,802	-7,576,453	-5,833,480	-3,507,011	-3,601,065	-3,538,171	790,041	3,993,599	-12,040	-8,350	-26,454	3,058,167	2,006,183	2,491,194	1,316,900
Stock	0	0	0	0	0	0	0	0	0	0	0	0	-45,558	-1,724	47,282
Debtors	26,704,124	5,663,505	6,400,798	7,028,011	-3,985,395	6,018,278	-2,979,788	7,781,083	-3,526,673	4,879,987	2,018,438	-2,845,204	1,209,056	1,817,227	1,231,540
Creditors	89,143	-259,533	-585,943	312,931	-306,161	351,361	206,263	-519,513	-336,294	1,173,838	-1,664,865	24,647	703,423	518,831	741,524
Accruals and Deferred Income	19,968,092	-1,291,841	1,324,834	631,908	1,543,192	-908,321	1,138,694	688,241	-312,018	-40,473,480	30,150,905	5,667,178	-4,276,836	-2,975,429	14,678,902
Deferred Taxes & Provisions	28,792	1,249,770	4,751,314	5,070,434	0	0	0	0	0	0	0	0	0	0	0
Cash flow from operations	124,710,237	61,990,341	44,700,016	35,041,256	39,637,927	23,440,247	15,590,921	18,949,911	12,805,092	-36,083,481	3,547,366	-4,836,390	-8,811,396	-8,554,455	12,354,482
Investing Activities
capital expenditure	-8,586,673	-8,682,483	-2,752,334	-11,011,039	-28,238,491	-4,120,025	-9,723,972	-6,429,415	-2,031,509	-2,031,004	-642,225	-743,570	-700,732	-441,069	-3,055,598
Change in Investments	657,443	3,069,426	-1,216,585	592,701	1,229,870	2,117,260	1,235,663	962,850	0	0	0	0	0	0	0
cash flow from investments	-9,244,116	-11,751,909	-1,535,749	-11,603,740	-29,468,361	-6,237,285	-10,959,635	-7,392,265	-2,031,509	-2,031,004	-642,225	-743,570	-700,732	-441,069	-3,055,598
Financing Activities
Bank loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Group/Directors Accounts	0	0	0	0	0	0	0	0	0	0	0	-199,357	199,357	0	0
Other Short Term Loans	0	0	0	0	0	0	0	0	0	0	0	0	0	-2,774,317	2,774,317
Long term loans	1,700,866	1,102,180	-3,252,642	-3,051,924	39,836,286	0	0	0	0	0	0	0	0	0	0
Hire Purchase and Lease Commitments	1,458,248	828,400	-1,643,465	-1,542,169	22,019,505	0	0	0	0	0	0	0	0	0	0
other long term liabilities	-645,277	303,544	241,806	500,630	139,844	0	0	0	0	0	0	0	0	0	0
share issue	0	0	0	0	-1,251,038	1	0	0	0	41,251,037	-429,698	235,588	181,671	1,124,859	18,088,695
interest	-2,139,372	4,239,411	182,237	-1,344,186	-969,351	195,965	-58,377	98,102	55,506	39,370	13,209	25,056	114,636	69,357	-531,549
cash flow from financing	374,465	6,473,535	-4,472,064	-5,437,649	59,775,246	195,966	-58,377	98,102	55,506	41,290,407	-416,489	61,287	495,664	-1,580,101	20,331,463
cash and cash equivalents
cash	37,693,210	5,715,724	14,678,468	-6,229,040	7,326,303	8,546,429	-25,184,374	12,234,404	10,829,089	6,177,953	2,515,106	-6,629,764	-1,959,793	-3,275,685	13,356,342
overdraft	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
change in cash	37,693,210	5,715,724	14,678,468	-6,229,040	7,326,303	8,546,429	-25,184,374	12,234,404	10,829,089	6,177,953	2,515,106	-6,629,764	-1,959,793	-3,275,685	13,356,342

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for astex therapeutics limited. Get real-time insights into astex therapeutics limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for astex therapeutics limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.

ASTEX THERAPEUTICS LIMITED group structure

Astex Therapeutics Limited has no subsidiary companies.

Ultimate parent company

OTSUKA HOLDINGS CO LTD

#0071689

OTSUKA AMERICA INC

#0043666

2 parents

ASTEX THERAPEUTICS LIMITED

03751674

ASTEX THERAPEUTICS LIMITED Shareholders

otsuka america inc

100%

Astex Therapeutics Limited currently has 5 directors. The longest serving directors include Harren Jhoti (May 1999) and Dr Robert McQuade (Jan 2014).

officer	country	age	start	end	role
Harren Jhoti		61 years	May 1999	-	Director
Dr Robert McQuade		67 years	Jan 2014	-	Director
Professor Sir Thomas Blundell	England	81 years	Jan 2014	-	Director
Mr Toshiki Sudo		55 years	May 2015	-	Director
Dr Yasuhisa Kurogi		59 years	Mar 2024	-	Director

P&L

December 2023

turnover

202.5m

+73%

operating profit

138.7m

+101%

gross margin

71.7%

+13.72%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

December 2023

net assets

136m

+0.53%

total assets

189.2m

+0.56%

cash

75.8m

+0.99%

net assets

Total assets minus all liabilities

Similar Companies

Agree?

oxford biomedica plc

4.5

oxford biomedica (uk) limited

charles river discovery research services uk limited

horizon discovery group plc

celltech r&d limited

company number

03751674

Type

Private limited with Share Capital

industry

72110 - Research and experimental development on biotechnology

incorporation date

April 1999

age

accounts

Full Accounts

ultimate parent company

OTSUKA HOLDINGS CO LTD

previous names

astex technology limited (June 2005)

intercede 1426 limited (May 1999)

incorporated

address

436 cambridge science park, milton road, cambridge, CB4 0QA

last accounts submitted

December 2023

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 2 charges/mortgages relating to astex therapeutics limited. Currently there are 0 open charges and 2 have been satisfied in the past.

astex therapeutics limited Company Information

astex therapeutics limited Estimated Valuation

astex therapeutics limited Estimated Valuation

astex therapeutics limited Estimated Valuation

Astex Therapeutics Limited Overview

Astex Therapeutics Limited Health Check

ASTEX THERAPEUTICS LIMITED financials

astex therapeutics limited Credit Report and Business Information

Astex Therapeutics Limited Competitor Analysis

astex therapeutics limited Ownership

astex therapeutics limited directors

astex therapeutics limited company details

astex therapeutics limited Charges & Mortgages

astex therapeutics limited Companies House Filings - See Documents